{"id":2693,"date":"2024-09-06T08:27:48","date_gmt":"2024-09-06T08:27:48","guid":{"rendered":"https:\/\/confolab.sav.sk\/ovsb\/?page_id=2693"},"modified":"2024-09-11T14:28:12","modified_gmt":"2024-09-11T14:28:12","slug":"cost-ca23156","status":"publish","type":"page","link":"https:\/\/confolab.sav.sk\/ovsb\/projekty\/aktivne-projekty\/cost-ca23156\/","title":{"rendered":"COST CA23156"},"content":{"rendered":"<p><script type=\"text\/javascript\">\n<!--\nfunction launch(newURL, newName, newFeatures, orgName) {\n  var remote = open(newURL, newName, newFeatures);\n  if (remote.opener == null)\n    remote.opener = window;\n  remote.opener.name = orgName;\n  return remote;\n}\n\nfunction launchRemote(name) {\n  var address =  name;\n  myRemote = launch(address ,\n                    \"Okno\",\n                    \"height=500, width=850, left=50, top=50, alwaysLowered=0, alwaysRaised=0, channelmode=0, dependent=0, directories=0, fullscreen=0, hotkeys=1, location=0, menubar=0, resizable=0, scrollbars=0, status=0, titlebar=1, toolbar=0, z-lock=0\",\n                    \"myWindow\");\n}\n\/\/ -->>\n<\/script><\/p>\n<h2>Eur\u00f3pske konzorcium pre sigma-1 receptor ako terapeutick\u00fd cie\u013e (SIGMA-1EUROPE) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<button onclick=\"goBack()\">Nasp\u00e4\u0165<\/button> <\/h2>\n<p><script>\t \t \nfunction goBack() { window.history.go(-1); }\t \t \n<\/script><\/p>\n<table border=\"0\" width=\"100%\" cellspacing=\"1\" cellpadding=\"2\">\n<tbody>\n<tr>\n<td>\n<h3>Ved\u00faci projektu: Tangui Maurice<br \/>\nVed\u00faci projektu (SK): <a href=\"https:\/\/confolab.sav.sk\/ovsb\/pracovnici\/vyskumnici\/rndr-michal-cagalinec-phd\/\">Michal Cagalinec<\/a><br \/>\nPracovisko v projekte vystupuje ako spolunavrhovate\u013e<\/h3>\n<h3>Trvanie: 2024 &#8211; 2028<br \/>\nKoordinuj\u00faca organiz\u00e1cia: M\u00e9canismes mol\u00e9culaires dans les d\u00e9mences neurod\u00e9g\u00e9n\u00e9ratives (MMDN), Institut national de la Sante et de la Recherche Medicale INSERM, Montpellier, France<br \/>\nKoordinuj\u00faca organiz\u00e1cia (SK): \u00dastav experiment\u00e1lnej endokrinol\u00f3gie BMC, v.v.i. SAV, Bratislava<\/h3>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<h3><span class=\"H3\">Anot\u00e1cia:<\/span><\/h3>\n<p>Sigma-1 receptor (S1R) je ligandom regulovan\u00fd chaper\u00f3nov\u00fd prote\u00edn endoplazmatick\u00e9ho retikula a je vhodn\u00fdm cie\u013eom novonavrhovan\u00fdch a novosyntetizovan\u00fdch terapeutick\u00fdch molek\u00fal na lie\u010dbu bolesti, neurodegenerat\u00edvnych a z\u00e1palov\u00fdch ochoren\u00ed ako aj rakoviny. Konzorcium SIGMA-1 EUROPE sp\u00e1ja discipl\u00edny a odborn\u00e9 znalosti v rade eur\u00f3pskych kraj\u00edn s cie\u013eom pokro\u010di\u0165 vo v\u00fdskume a identifik\u00e1cii \u00falohy S1R vo fyziol\u00f3gii a patofyziol\u00f3gii, navrhn\u00fa\u0165 inovat\u00edvne ligandy S1R pre bunkov\u00fa biol\u00f3giu a medic\u00ednu a v neposlednom rade prostredn\u00edctvom spolupr\u00e1c a tr\u00e9ningov\u00fdch aktiv\u00edt pre mlad\u00fdch v\u00fdskumn\u00edkov a inov\u00e1torov m\u00e1 za cie\u013e, aby t\u00edto roz\u0161\u00edrili svoje obzory, aby prem\u00fd\u0161\u013eali komplexne a s\u00favislostiach aj mimo ich vednej \u0161pecializ\u00e1cie a sk\u00famali nov\u00e9 a inovat\u00edvne terapeutick\u00e9 mo\u017enosti t\u00fdchto ochoren\u00ed.<\/td>\n<\/tr>\n<tr>\n<td>\n<h3><span class=\"H3\">K\u013e\u00fa\u010dov\u00e9 slov\u00e1:<\/span><\/h3>\n<p>farmakol\u00f3gia, v\u00fdvoj lie\u010div, transla\u010dn\u00fd v\u00fdcvik, cytoprotekcia, boles\u0165<\/td>\n<\/tr>\n<tr>\n<td>\n<h3><span class=\"H3\">Ciele:<\/span><\/h3>\n<p>1. N\u00e1vrh liekov, modelovanie, r\u00e1dioakt\u00edvne indik\u00e1tory<br \/>\n2. S1R pri neurodegenerat\u00edvnych, z\u00e1palov\u00fdch, rakovinov\u00fdch a kardiometabolick\u00fdch ochoreniach<br \/>\n3. Stanovenie SOP pre in vitro a in vivo modely na hodnotenie S1R ligandov<br \/>\n4. Po\u017eiadavky priemyseln\u00fdch strat\u00e9gi\u00ed na v\u00fdvoj liekov<br \/>\n5. Disemin\u00e1cia, komunik\u00e1cia a dosah\n<\/td>\n<\/tr>\n<tr>\n<td>\n<h3><span class=\"H3\">Publik\u00e1cie:<\/span><\/h3>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<table class=\"list\" border=\"0\" width=\"100%\" cellspacing=\"0\" cellpadding=\"4\">\n<tbody>\n<tr>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Eur\u00f3pske konzorcium pre sigma-1 receptor ako terapeutick\u00fd cie\u013e (SIGMA-1EUROPE) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nasp\u00e4\u0165 Ved\u00faci projektu: Tangui Maurice Ved\u00faci projektu (SK): Michal Cagalinec Pracovisko v projekte vystupuje ako spolunavrhovate\u013e&#8230;<span class=\"excerpt_more\"><a href=\"https:\/\/confolab.sav.sk\/ovsb\/projekty\/aktivne-projekty\/cost-ca23156\/\">\u010d\u00edta\u0165 \u010falej &raquo;<\/a><\/span><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":116,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/confolab.sav.sk\/ovsb\/wp-json\/wp\/v2\/pages\/2693"}],"collection":[{"href":"https:\/\/confolab.sav.sk\/ovsb\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/confolab.sav.sk\/ovsb\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/confolab.sav.sk\/ovsb\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/confolab.sav.sk\/ovsb\/wp-json\/wp\/v2\/comments?post=2693"}],"version-history":[{"count":11,"href":"https:\/\/confolab.sav.sk\/ovsb\/wp-json\/wp\/v2\/pages\/2693\/revisions"}],"predecessor-version":[{"id":2705,"href":"https:\/\/confolab.sav.sk\/ovsb\/wp-json\/wp\/v2\/pages\/2693\/revisions\/2705"}],"up":[{"embeddable":true,"href":"https:\/\/confolab.sav.sk\/ovsb\/wp-json\/wp\/v2\/pages\/116"}],"wp:attachment":[{"href":"https:\/\/confolab.sav.sk\/ovsb\/wp-json\/wp\/v2\/media?parent=2693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}